Epithalon

• Research applications include AEDG identity and impurity-method development, telomerase and telomere-maintenance assays, comparison of normal and cancer cell responses, histone or gene-expression hypotheses, retinal models and critical replication of a concentrated evidence base
• Reported lifespan, sleep, retinal or anti-ageing outcomes are study-specific observations, not product benefits.

CAS

307297-39-8

Formula

C₁₄H₂₂N₄O₉

Molecular weight

390.35 g/mol

Appearance

Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA

Purity

Lot-specific chromatographic purity and quantitative peptide content; confirm both on the released-lot COA · target, verify batch COA

Storage

Follow the released-lot COA, SDS and formulation-specific stability statement. Temperature, light protection, shipping range, container and any prepared-solution hold time require evidence for the exact AEDG form, counterion, matrix and concentration; no universal 2–8 °C, -20 °C, 30-day or bacteriostatic-water rule applies.

MOQ

1 kit (10 vials) per SKU

Lead time

7–14 days

Epitalon, also spelled Epithalon, is the sequence-defined tetrapeptide H-Ala-Glu-Asp-Gly-OH (AEDG). PubChem CID 219042 lists formula C₁₄H₂₂N₄O₉, molecular weight 390.35 g/mol and CAS 307297-39-8. It was developed in the Khavinson research lineage as a synthetic peptide associated with the heterogeneous bovine pineal extract Epithalamin; the two materials are not analytically or evidentially interchangeable. Most human and animal literature comes from that lineage. A 2025 independent cell study adds laboratory evidence but received a correction and does not establish human longevity or safety. The May 12, 2026 FDA briefing states that the nominations of Epitalon free base and Epitalon acetate were withdrawn, that FDA is evaluating them on its own initiative and that the available criteria weigh against Section 503A Bulks List placement. PCAC discussion is scheduled for July 24, 2026; scheduling is not approval or a final FDA determination.

• Sequence and identity qualification; stability-indicating analytics; controlled telomerase, telomere, ALT, histone, gene-expression and retinal-model research; and independent replication of lineage-concentrated findings
• These are research applications, not clinical indications or anti-ageing claims.

In-vitro work reports hTERT expression and telomerase-associated telomere extension in selected normal cells. The corrected 2025 study reported telomere extension through hTERT/telomerase upregulation in IBR.3 and HMEC normal cells and through alternative lengthening of telomeres (ALT) in 21NT and BT474 breast-cancer cells. Histone-binding, gene-expression, melatonin and antioxidant pathways remain model-dependent hypotheses. These findings do not establish a human mechanism, clinical benefit or safety.

• Not for human or veterinary use
• In its 2026 briefing, FDA found no pharmacokinetic data and no clinical studies assessing human safety for Epitalon-related bulk substances
• Absence of reports in searched passive databases does not establish safety
• Telomere extension in breast-cancer cell lines is an in-vitro mechanistic observation, not proof of human carcinogenicity, but it underscores the absence of an adequate clinical safety assessment
• Follow the released-lot SDS and institutional controls.

Interactions reported in the literature

• No controlled combination or patient drug-interaction programme was identified
• Pairings with melatonin, Thymalin, NAD+ precursors, growth-hormone-related peptides, BPC-157, Semax, Selank or Cortexin are not validated compatibility, synergy or safety guidance.

Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount

• 10 mg
• 50 mg

Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.

Independent test fails? Full refund.

On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep

Ask for the current packet, not a generic certificate

• Require exact AEDG sequence and termini, free-base or salt assignment, counterion, theoretical and observed high-resolution intact mass, orthogonal sequence evidence where appropriate, stability-indicating HPLC purity and impurity profile, quantitative peptide content, water/counterion/residual solvents and lot-specific stability
• Sterility, bacterial endotoxin and particulate claims require separate released-lot tests
• Appearance, solution clarity or a generic ≥99% area result cannot establish identity, content or suitability.

Follow the released-lot COA, SDS and formulation-specific stability statement. Temperature, light protection, shipping range, container and any prepared-solution hold time require evidence for the exact AEDG form, counterion, matrix and concentration; no universal 2–8 °C, -20 °C, 30-day or bacteriostatic-water rule applies.

State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.

• Identity: PubChem CID 219042. Cellular evidence: PubMed PMID 12937682; the 2025 Biogerontology study, PMID 40908429 and PMCID PMC12411320; and its November 2025 correction, PMID 41240216 and PMCID PMC12619744. Human retinal context: PMID 12195242, interpreted within its limited reporting and single-lineage setting. Regulatory status and evidence gaps: FDA briefing dated May 12, 2026 and the official July 23–24, 2026 PCAC meeting page; FDA also records the former retinitis-pigmentosa orphan designation as withdrawn or revoked and not approved.

1. 01

   Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells

   Bulletin of Experimental Biology and Medicine · 2003 · peer-reviewed original research (in vitro)

   Open source
2. 02

   Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity

   Biogerontology · 2025 · peer-reviewed original research (in vitro)

   Open source
3. 03

   Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties

   International Journal of Molecular Sciences · 2025 · peer-reviewed review article

   Open source
4. 04

   Therapeutic peptides in gerontology: mechanisms and applications for healthy aging

   Frontiers in Aging · 2026 · peer-reviewed review article

   Open source
5. 05

   Peptides of pineal gland and thymus prolong human life

   Neuroendocrinology Letters · 2003 · clinical follow-up study (non-blinded, non-placebo-controlled)

   Open source
6. 06

   Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up

   Bulletin of Experimental Biology and Medicine · 2011 · clinical follow-up study (non-blinded)

   Open source
7. 07

   Evaluation of Epitalon-Related Bulk Drug Substances for Inclusion on the 503A Bulk Drug Substances List

   U.S. Food and Drug Administration / Pharmacy Compounding Advisory Committee · 2026 · official regulatory briefing document

   Open source

• How to read a peptide COA without confusing purity, identity and content
• Peptide purity versus peptide content: a buyer’s method map
• Questions to ask a research peptide supplier before the first purchase order